BioNano Genomics Inc vs 3M Company — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while 3M Company trades at $183.53 (market cap $94.44B). The key difference: 3M Company is far larger — about 6913.6× BioNano Genomics Inc's market cap, and 3M Company pays a 1.7% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MMM | |
|---|---|---|
Market Cap | $13.66M | $94.44B |
Sector | Health | Industrials |
52-Week High | $4.92 | $183.13 |
52-Week Low | $1.06 | $141.10 |
Enterprise Value | $16.26M | $103.67B |
Dividend Yield | — | 1.7% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
3M (MMM) trades at $183.58, up 0.85% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding expectations by 6.7%, and raised full-year guidance. Revenue trends show stabilization after 2023 challenges, with 2025 revenue of $24.95B and net income margin of 13.02%. Analyst sentiment is mixed with 48% buy ratings but the stock trades above the consensus price target of $173.
The outlook remains positive with operational improvements and innovation driving growth, particularly in Safety & Industrial and Transportation segments. Key risks include litigation liabilities, macroeconomic headwinds, and valuation concerns with elevated P/E of 32.5. The EBO partnership with Microsoft presents long-term data center growth opportunities, though current pricing may limit near-term upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →